Monitor the outcome of BioTissue Clearance Payment negotiations — a default or restructuring could signal deeper liquidity stress. The 30-day equity issuance standstill and 6-month variable rate ban limit near-term dilution but the unresolved $10M payment is a material overhang. Watch for any subsequent 8-K regarding the Clearance Payment or additional financing.
Price Chart
Executive Summary
BioStem Technologies raised approximately $3.0 million in a private placement priced at-the-market under Nasdaq rules, issuing 735,296 shares of common stock at $4.08 per share along with Series A and Series B warrants to purchase up to an additional 1,470,592 shares at $3.83 per share. The company also disclosed that a $10.0 million payment owed to BioTissue Holdings for a 510(k) clearance milestone remains unpaid and is under negotiation, adding financial overhang. The combination of dilutive equity issuance and a material unpaid obligation creates a bearish signal for existing shareholders.
Key Financial Metrics
Key Facts
- Gross proceeds of ~$3.0 million from sale of 735,296 shares at $4.08/share plus warrants for up to 1,470,592 additional shares at $3.83/share.
- Series A warrants expire 5 years after effective date of resale registration statement; Series B warrants expire 24 months after.
- Full cash exercise of all warrants would yield additional ~$5.6 million in proceeds.
- Company has not made a $10.0 million Clearance Payment to BioTissue Holdings that was due September 15, 2026, and is in ongoing discussions regarding timing and terms.
- Proceeds from the offering are intended for working capital and general corporate purposes, including the BioTissue Clearance Payment.
- Placement agent H.C. Wainwright received a 7.0% cash fee and warrants to purchase 18,382 shares at $6.12/share.
- Company agreed to a 30-day standstill on further equity issuances and a 6-month ban on variable rate transactions after the effective date.
Financial Impact
Dilution of ~7.3% from the 735,296 shares issued (based on prior outstanding), with potential additional dilution of ~14.6% if all warrants exercised. $10.0M Clearance Payment obligation unresolved.
Risk Factors
- Failure to make the $10.0M Clearance Payment could trigger default under the BioTissue asset purchase agreement.
- Full warrant exercise would add significant dilution (~1.47M shares) with no guaranteed proceeds.
- Company may need additional capital if Clearance Payment is not restructured or waived.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-409169 |
| Document: bsem-ex10_2.htm | 0001193125-26-409169 |
| Document: bsem-ex4_1.htm | 0001193125-26-409169 |
| Document: bsem-ex99_1.htm | 0001193125-26-409169 |
| Document: bsem-20260929.htm | 0001193125-26-409169 |
| Document: 0001193125-26-409169-index-headers.html | 0001193125-26-409169 |
| Document: 0001193125-26-409169-index.html | 0001193125-26-409169 |
| Document: 0001193125-26-409169.txt | 0001193125-26-409169 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | EFFECT | $2.25 $2.11 | ▲ +6.22% | ▲ +5.14% | $1.54 (+31.56%) |
Oct 2, 2026 24d ago | S-1 | $2.76 $2.47 | ▲ +10.34% | ▲ +10.89% | $1.54 (+44.10%) |
Sep 30, 2026 26d ago | 8-K | $3.07 $2.73 | ▲ +11.07% | ▲ +11.81% | $1.54 (+49.84%) |
Sep 30, 2026 27d ago | EFFECT | $3.09 $3.07 | ▲ +0.65% | ▲ +0.83% | $1.54 (+50.16%) |
Sep 21, 2026 5w ago | Press Release | $3.98 $3.80 | ▼ −4.52% | ▼ −3.80% | $1.54 (−61.31%) |
Sep 18, 2026 5w ago | S-1 | $4.40 $3.98 | ▲ +9.55% | ▲ +9.53% | $1.54 (+65.00%) |
Sep 18, 2026 5w ago | Press Release | $4.74 $4.40 | ▲ +7.17% | ▲ +8.72% | $1.54 (+67.51%) |
Aug 14, 2026 10w ago | 3 | $3.00 $3.15 | ▲ +5.00% | ▲ +5.68% | $1.54 (−48.67%) |
Aug 14, 2026 10w ago | 3 | $3.00 $3.15 | ▲ +5.00% | ▲ +5.68% | $1.54 (−48.67%) |
Jul 29, 2026 12w ago | S-1 | $3.29 $3.20 | ▲ +2.74% | ▲ +4.41% | $1.54 (+53.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers